03-05-2025
CPHI South East Asia 2025: Your gateway to ASEAN's expanding pharmaceutical landscape
KUALA LUMPUR, Malaysia, May 2, 2025 /PRNewswire/ -- As Southeast Asia's pharmaceutical industry rapidly evolves—driven by regulatory harmonization, innovation, and growing healthcare demand—CPHI South East Asia 2025 provides a vital platform to connect with regional stakeholders, showcase breakthroughs, and unlock business opportunities across the ASEAN region.
Taking place for the first time in Kuala Lumpur, Malaysia, from 16–18 July 2025, the event will bring together 8,000+ professionals, 400+ global exhibitors, and curated buyers from across Asia and beyond—positioning it as the region's most impactful pharma event.
Unlock Growth Across ASEAN's Pharma Markets
From Indonesia, Thailand, Vietnam, the Philippines to Malaysia, Southeast Asia is one of the world's most dynamic pharmaceutical regions. Governments are investing in local manufacturing, reforming regulatory systems, and opening doors to international partnerships.
Malaysia, as this year's host, plays a central role in this growth. [1] The country's pharmaceutical market is expected to rise from RM11.2 billion in 2022 to RM15.5 billion by 2027, supported by the New Industrial Master Plan (NIMP) 2030, which incentivizes the production of APIs, biologics, and vaccines.
[2] Strategically located between Singapore and Indonesia, Malaysia offers streamlined access to regional distributors, CDMOs, and packaging partners—making Kuala Lumpur a strategic gateway to ASEAN-wide expansion.
